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ABSTRACT
The ischaemic cascade is the concept that progressive
myocardial oxygen supply–demand mismatch causes a
consistent sequence of events, starting with metabolic
alterations and followed sequentially by myocardial
perfusion abnormalities, wall motion abnormalities,
ECG changes, and angina. This concept would suggest
that investigations that detect expressions of ischaemia
earlier in the cascade should be more sensitive tests of
ischaemia than those that detect expressions appearing
later in the cascade. However, careful review of the
studies on which the ischaemic cascade is based
suggests that the ischaemic cascade concept may be
less well supported by the literature than assumed. In
this review we explore this, discuss an alternative
method for conceptualising ischaemia, and discuss the
potential implications of this new approach to clinical
studies and clinical practice.
INTRODUCTION
The ischaemic cascade was initially described
over 20 years previously,1 based on experi-
ments in animals2–9 and humans,10–20 and
refers to a temporal sequence of patho-
physiological events that occur with increas-
ing myocardial oxygen supply–demand
imbalance. The ischaemic cascade has been
described as occurring in the following
sequence: metabolic alterations, inducible
changes of perfusion, diastolic dysfunction,
regional systolic wall motion dysfunction,
ischaemic ECG changes and finally angina.1
A cascade is a sequence of events, each of
which triggers the next. Since causation is dif-
ficult to demonstrate directly, instead progres-
sion is demonstrated and causation inferred.
To create progressively more intense ischae-
mia within an individual animal, so that the
sequence of emergence of elements of the
cascade can be identified, three broad
approaches are possible (figure 1):
▸ Progressively tighter stenosis, with workload
kept constant and measured at steady state.
▸ Progressive passage of time after a fixed
acute occlusion, with workload kept
constant.
▸ Progressively increasing workload, with
stenosis kept constant and measured at
steady state.
Assembling data from experiments that use
different possibilities from the three ways of
spreading ischaemia intensity on a spectrum
relies on the assumption that the three dif-
ferent meanings of increasing ischaemia are
equivalent. If the ischaemic cascade model is
accurate, the order of events should be the
same in all three. For example, it might be
metabolic alterations first, followed sequen-
tially by myocardial perfusion abnormalities,
wall motion abnormalities, ECG changes and
angina. If this assumption is not correct then
we should be much more thoughtful when
displaying illustrations of the process of
ischaemia.
Metabolic alterations consist of the conver-
sion from aerobic to anaerobic myocardial
cell metabolism, thus producing biochemical
changes of lactate, and cellular polarity. At a
single-cell level a cascade is feasible, however
cellular events will not occur synchronously in
all cells beyond a stenosis. It is the later stages
of the ischaemic cascade concept that are of
clinical interest, but these can be subject to
confounding effects of concomitant medica-
tions and varying degrees of coronary disease.
If the ischaemic cascade is not as solid a
sequence as is often portrayed, this article
discusses how the process of ischaemia could
be conceptualised, the implications this has
on the development of new tests of ischae-
mia and the implications for clinical practice.
Some clinicians and scientists may have
already rejected the ischaemic cascade for
not being true; for them, our paper is attack-
ing a ‘straw man’. Unfortunately however,
figures and slides are commonly shown21–24
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and clinical studies (that use a single ‘gold standard’ for
ischaemia) continue to assume that the cascade is true.
This implies that rejection of the ischaemic cascade is
not yet universal, and therefore our paper may be a
useful enumeration of information.
METHODS
Literature search was performed in accordance to the
PRISMA statement.25 Studies were identified by search-
ing Medline (1946 to February 2015) and Embase (1974
to February 2015), using the search term ‘ischaemic
cascade’ (both English and American spellings). The
search was restricted to English language and case
reports were excluded. Reference lists of the retrieved
articles (including reviews and editorials) were hand-
searched for additional publications. The methodo-
logical validity of each included study was assessed using
criteria for minimisation of bias, including definition
and measurement of outcome, blinding, presence of a
control group, and sample size (figure 2).
FOUNDATIONS OF THE ISCHAEMIC CASCADE
The original paper,1 describing the ischaemic cascade,
was based on human studies10–20 (table 1). The methods
used to induce supply–demand mismatch were as
follows: (1) coronary artery balloon occlusion,10–12 (2)
atrial pacing tachycardia,13–15 (3) exercise testing16–19
and (4) spontaneous angina,20 that is, episodes of myo-
cardial ischaemia at rest (either spontaneous or ergono-
vine induced) in patients with Prinzmetal’s angina.
It is far from clear whether the events after abrupt
occlusion of a coronary artery, coronary vasospasm, or
increased myocardial workload, match what happens in
incremental ischaemia with chronic coronary artery sten-
osis. Nonetheless, these studies10–20 show that angina
and/or ST segment depression does not consistently
accompany ischaemia. More importantly, they show that
when angina and/or ST segment depression do occur,
their temporal relationship with other elements of the
ischaemic cascade is not always what would be expected
if the cascade is correct. Studies that support the
sequence of events in the ischaemic cascade are sum-
marised in table 1.10 11 13–15 17 19 20 26–31 Table 2 sum-
marises studies that contradict the sequence of events
described in the ischaemic cascade.12 16 18 32–34
SEQUENCE MISMATCHES
The term ‘cascade’ is a reference to a sequence of
events, each triggering the next. It is used to describe
waterfalls, where what falls to one level becomes avail-
able to fall to the next level down (figure 3). If, however,
events are observed to occur out of sequence, then
impression of causality (or at least ordering) conveyed
by the term ‘cascade’ may not be secure.
Close inspection and comparison of the results of dif-
ferent studies, included in the original ischaemic cascade
concept paper,1 suggests that the sequence of events
described is not conserved across patients (table 2). For
instance, one study18 found that when diastolic dysfunc-
tion was measured using pulmonary artery pressure
during exercise, the onset of ST segment depression
occurred before diastolic dysfunction in 38% of episodes,
was simultaneous with it in 38% of episodes, and followed
it in only 24% of episodes.
In another study of patients with angina who underwent
continuous ECG and echocardiographic monitoring
Figure 1 Three different ‘x axes’
along which to rank states for
ischaemia. The underlying
hypothesis behind the ischaemic
cascade is that the order of
development of the various
manifestations of ischaemia is the
same for all three main ways of
producing the ischaemia
phenomenon. One approach is to
ligate a coronary artery and
monitor carefully in the ensuing
seconds, with the temporal
sequence of events showing the
cascade sequence. A second is
to progressively increase
stenosis. A third is to
progressively increase workload.
If these three methods of
inducing progressively more
severe ischaemia produce
manifestations in conflicting
sequences, the ischaemic
cascade concept is imperilled.
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during dipyridamole infusion, the sequence of ischaemic
events observed were markedly variable.33 Of those
patients who developed echocardiographic and ECG
changes/angina, only about half exhibited regional wall
motion abnormalities first, while the remaining half exhib-
ited ECG changes and or angina first.
In a further study of 707 consecutive patients screened
after dobutamine or bicycle ergometer stress echocardi-
ography, only 12% of patients followed the classical
ischaemic cascade.32 Only 30% had regional perfusion
defects prior to the onset of abnormal wall motion,
whereas 22% had perfusion defects seen during or after
the onset of abnormal wall motion.32 These findings
and those of others33 34 contradict the sequence of
events described in the ischaemic cascade.
THE ISCHAEMIC CONSTELLATION
In light of the data conflicting with the concept of any
single ischaemic cascade, perhaps the concept of a single
sequence of stepwise causality needs to be re-evaluated.
In a true cascade, where each event leads to the next
in succession, there is no doubt regarding the causal
sequence of events. For example, in the complement
cascade of the immune system each stage is necessary
for the next to occur.
In contrast to a cascade model of ischaemia, we
propose that a more befitting model of myocardial
ischaemia may be the ‘ischaemic constellation’; a collec-
tion of observations that may occur in a variety of
sequences. An ischaemic constellation would include all
clinical aspects of the cascade, including angina, myocar-
dial perfusion abnormalities, ST segment depression
and wall motion abnormalities, without the artificial pre-
requisite of a need to occur in a particular preordained
order. Such a constellation would explain the similar
rate of positivity of tests of ischaemia and their variable
ordering of apparent sensitivity in different patients.35
Conceptualising ischaemia in this way would perhaps
be more consistent with clinical practice. Currently, clini-
cians who would otherwise be restricted by the concept
Figure 2 Flow diagram of
literature search.
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of the ischaemic cascade tend to adopt an approach to
ischaemia testing that is driven by an underlying pretest
suspicion as to the likelihood of ischaemia. For example
a negative ischaemia test in a patient with typical angina
will trigger a further investigation, with a test that may
not necessarily be upstream the cascade. This behaviour
is not consistent with trust in an ischaemic cascade. It
suggests that physicians are ready to accept that it is bio-
logically plausible that both tests are ‘correct’ but having
different results. Clinically this means that physicians
may tailor the use of specific ischaemia tests to specific
populations.36 However, this contrasts with clinical trials
comparing ischaemia tests in which investigators appoint
a ‘gold standard’, which is assumed to be the most sensi-
tive test in all patients.37 38 Such an approach does not
appreciate variation between individuals and therefore
squanders an opportunity to understand which tests are
most appropriate for specific populations.
SCIENTIFIC AND CLINICAL IMPLICATIONS
The scientific and clinical implications of a ‘constella-
tion’ model of ischaemia, rather than the ‘cascade’
model, are pertinent to the key question of whether
ischaemia is present when two tests have conflicting
results. This is a common challenge in the interpretation
of validation studies of new tests of ischaemia. Currently
any disagreement of the new test with the test appointed
as ‘gold standard’ is interpreted as an inaccuracy of the
new test. Recently this approach has been demonstrated
to be flawed.35 39
A ‘constellation’ model of ischaemia could provide a
solution to the problem of how to interpret investiga-
tions when conflicting test results coexist in the same
patient and thereby resolve a crisis for those relying on
the ischaemic cascade as a schema for interpretation of
events. The constellation would suggest that in such a
situation both tests may be correct, but one biological
event may have occurred at a lower degree of ischaemia
than the other event in that particular individual.
Importantly, the converse may be true in another indi-
vidual—a possibility that cannot be encompassed with a
cascade.
The ‘constellation’ does not provide a solution to the
problem of how to differentiate a false-positive test from
the situation of conflicting results from two tests in the
same patient. One way to resolve this would be a study
design that doesn’t simply compare one test to another,
but evaluates the test’s ability to predict improvement of
symptoms when the patient receives appropriate therapy,
such as antianginal medications. For example, a trial
design that may help evaluate the clinical accuracy of a test
may involve randomising patients, who test negative or
positive for an investigation of ischaemia, to antianginal
medications or placebo, and measuring symptomatic and
or functional outcomes (figure 4). An objective
Table 1 Summary of human studies that support the sequence of events in the ischaemic cascade
Study Sample size Ischaemic state Blinded study
Sestito et al30 30 Dipyridamole stress echocardiography Not reported
Kyrzopoulos et al31 148 Dobutamine stress echocardiography Not reported
Heller et al29 19 Exercise testing Yes
Williams et al28 104 Bicycle ergometer stress echocardiography Not reported
Nixdorff et al27 16 Bicycle ergometer stress echocardiography Yes
Hyodo et al26 53 Dobutamine stress echocardiography Yes
Alam et al10 12 Coronary artery occlusion No
Hauser et al11 18 Coronary artery occlusion Not reported
McLaurin et al13 15 Rapid atrial pacing Not reported
Iskandrian et al14 12 Rapid atrial pacing Not reported
Aroesty et al15 22 Rapid atrial pacing Not reported
Reduto et al17 68 Exercise testing Not reported
Berger et al 197919 73 Exercise testing Not reported
Distante et al20 12 Patients with Prinzmetal’s angina (spontaneous
angina, or induced by ergonovine)
Not reported
Table 2 Summary of human studies illustrating the concept of the ischaemic constellation
Study Sample size Ischaemic state Blinded study
Choy et al32 707 Dobutamine or bicycle ergometer stress echocardiography Not reported
Sigwart et al12 12 Coronary artery occlusion Not reported
Levy et al18 25 Exercise testing Not reported
Amsterdam et al16 92 Exercise testing Not reported
Gaspardone et al33 21 Dipyridamole infusion Yes
Cannon et al34 42 Dobutamine infusion No
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assessment of patient functional status such as cardiopul-
monary exercise testing could be used to assess the
patient’s symptoms and functional capacity, thus providing
an objective, reproducible and quantifiable measure. The
most reliable test would be that which most consistently
predicts whether the patient will improve symptomatically,
or functionally (in patients with ‘silent’ ischaemia), with
treatment versus placebo. Such an approach uses the
patient’s symptoms and functional capacity (with placebo
control) as the reference standard.
It should be noted that there are several different
causes of ischaemia and therefore, the treatment success
of individual pharmacological agents will vary according
to the cause of ischaemia. Our study design would there-
fore require identification of the predominant cause of
ischaemia prior to enrollment of the patients into the
study. For example, separating those with angina and
epicardial coronary disease from those with angina and
‘normal’ epicardial arteries. This is not unusual in this
field, for example the fractional flow reserve (FFR)
studies have routinely stipulated a minimum amount of
epicardial disease that patients must have prior to enroll-
ment.40–42
The external applicability of a clinical trial result to
different patient populations applies to all clinical
studies. The efficacy of any given treatment will vary
according to the individual characteristics of the popula-
tion being treated. While our study design addresses the
concept of an ischaemic constellation the external
applicability of its results to different patient populations
will be vulnerable to the limitations of any clinical trial.
While this has been commonly acknowledged in
pharmacology studies (eg, ACE inhibitors in black vs
white populations43) it is only now being more widely
acknowledged in the ischaemia diagnostic domain.
Recent studies have confirmed that the accuracy of diag-
nostic tests will vary according to the underlying distribu-
tion of stenoses in differing populations.44 Furthermore,
the treatment threshold of certain diagnostic tests may
vary according to age and gender.45 46
Despite the above limitations, which are shared with
existing trial design, the constellation model begins the
process of acceptance that a single gold standard test for
ischaemia may not be possible. The reasoning above sug-
gests that there may well be multiple tests, each individu-
ally accurate in describing one facet of the constellation,
but mutually conflicting without any necessarily being
erroneous. Explicit public recognition of this might
open the way for clinicians to interpret studies compar-
ing ischaemia tests in a more rational manner. A first
step to permitting this personalised and integrative car-
diology would be to recognise that information from
these quantitative tests is continuous rather than
dichotomous.
SUMMARY
In this review we have indicated that (1) it is unwise to
describe the clinical manifestations of ischaemia as a
cascade, (2) it may be unwise to speak of the sensitivity
or specificity of a test for ischaemia, since there may be
no true gold standard and (3) when the results of clin-
ical tests differ we may need to take a more sophisticated
approach than saying one is right and the other is
wrong.
CONCLUSION
For decades the ischaemic cascade has been at the foun-
dations of teaching regarding diagnosis of ischaemia.
Review of the source literature suggests, however, that it
is not correct, with components of the cascade often
occurring out of sequence. Presenting information
known to be incorrect may be convenient for the short-
term aim of providing educational content, but does not
Figure 3 Waterfall analogy of the ischaemic cascade. In a
cascade the water falling down one step is the water that is
available to later fall down the next step. The water must fall
down the steps in sequence. If water was found to be moving
out of sequence, that is, up and down between steps in an
unpredictable way, then it is not a cascade.
Figure 4 Illustration of a trial design to help evaluate the
clinical accuracy of a test of ischaemia. The best test would
result in improved symptoms in those patients who test
positive and are randomised to antianginal treatment, with no
change in symptoms in those who test positive and are
randomised to placebo, or after treatment for those who test
negative.
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necessarily help the long-term aim of improving scien-
tific knowledge about important processes in humans.
We propose the ‘ischaemic constellation’, a paradigm
that recognises no single gold standard test for ischae-
mia and that different markers of ischaemia may
become abnormal at different stages depending on the
individual, the nature of stimulus to ischaemia, and
other factors, and that results may vary between one
episode and another. This ‘constellation concept’ calls
for a new way of evaluating ischaemia tests that places
the patient as the ‘gold standard’.
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